New strategies in chronic lymphocytic leukemia: Shifting treatment paradigms

Clinical Cancer Research

Volumn 20, Issue 23, 2014, Pages 5869-5874

  Awan, Farrukh T ^a   Byrd, John C ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; B LYMPHOCYTE RECEPTOR; CYCLOPHOSPHAMIDE; CYTARABINE; FLAVOPIRIDOL; FLUDARABINE; IBRUTINIB; IDELALISIB; LENALIDOMIDE; LYMPHOCYTE ANTIGEN RECEPTOR; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; RITUXIMAB; STEROID; VENETOCLAX; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ANTIBODY DETECTION; APOPTOSIS; ARTICLE; BINDING SITE; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLITIS; CYTOPENIA; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FAILURE FREE SURVIVAL; FEBRILE NEUTROPENIA; HEART ATRIUM FIBRILLATION; HUMAN; INFECTION; LYMPHOCYTOSIS; MINIMAL RESIDUAL DISEASE; PNEUMONIA; PROGRESSION FREE SURVIVAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; THROMBOCYTE DYSFUNCTION; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTEIN KINASE INHIBITORS;

EID: 84918536030     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-1889     Document Type: Article

References (45)

1. Buckley RH. Primary immunodeficiency diseases due to defects in lymphocytes. N Engl J Med 2000;343:1313-24.
2. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011;117:6287-96.
3. Duhren-Von Minden M, Ubelhart R, Schneider D, Wossning T, Bach MP, Buchner M, et al. Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling. Nature 2012;489:309-12.
4. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood 2013;122:2539-49.
5. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013;369:32-42.
6. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an openlabel, multicentre, phase 1b/2 trial. Lancet Oncol 2014;15:48-58.
7. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. Blood 2014;123:1810-7.
8. So L, Fruman DA. PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances. Biochem J 2012;442:465-81.
9. Bunney TD, Katan M. Phosphoinositide signalling in cancer: beyond PI3K and PTEN. Nat Rev Cancer 2010;10:342-52.
10. Chantry D, Vojtek A, Kashishian A, Holtzman DA, Wood C, Gray PW, et al. p110delta, a novel phosphatidylinositol 3-kinase catalytic subunit that associates with p85 and is expressed predominantly in leukocytes. J Biol Chem 1997;272:19236-41.
11. Herman SE, Gordon AL, Wagner AJ, Heerema NA, Zhao W, Flynn JM, et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood 2010;116:2078-88.
12. Brown JR, Byrd JC, Coutre SE, Benson DM, Flinn IW, Wagner-Johnston ND, et al. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110delta, for relapsed/refractory chronic lymphocytic leukemia. Blood 2014;123:3390-7.
13. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA, et al. Longterm results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 2008;112:975-80.
14. Strati P, Keating M, O'Brien S, Burger J, Ferrajoli A, Jain N, et al. Early bone marrow MRD negativity with first-line FCR in CLL may prompt consideration of stopping treatment [abstract]. In: 15th International Workshop on Chronic Lymphocytic Leukaemia (iwCLL 2013); 2013 Sep. 9-11; Cologne, Germany; 2013. p. 5. Abstract nr 21.
15. Strati P, Wierda W, Burger J, Ferrajoli A, Tam C, Lerner S, et al. Myelosuppression after frontline fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: analysis of persistent and new-onset cytopenia. Cancer 2013;119:3805-11.
16. Godiwala N, Maddocks K, Westbrook TB, Byrd J, Andersen B, Johnson A. Covariation of psychological and inflammatory variables in patients with chronic lymphocytic leukemia receiving ibrutinib. J Clin Oncol 32:5s, 2014(suppl; abstr 7057).
17. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med 2014;370:997-1007.
18. Zhou Y, Tang G, Medeiros LJ, McDonnell TJ, Keating MJ, Wierda WG, et al. Therapy-related myeloid neoplasms following fludarabine, cyclophosphamide, and rituximab (FCR) treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma. Mod Pathol 2012;25:237-45.
19. Burger JA, Keating MJ, Wierda WG, Hartmann E, Hoellenriegel J, Rosin NY, et al. Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study. Lancet Oncol 2014;15:1090-9.
20. Kamel S, Horton L, Ysebaert L, Levade M, Burbury K, Tan S, et al. Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation. Leukemia 2014 Aug. 20. [Epub ahead of print].
21. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med 2014;371:213-23.
22. Burger JA, Keating MJ, Wierda WG, Hoellenriegel J, Ferrajoli A, Faderl S, et al. The Btk inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients. Blood 2012;120:187.
23. Strati P, Keating MJ, O'Brien SM, Ferrajoli A, Burger J, Faderl S, et al. Outcomes of first-line treatment for chronic lymphocytic leukemiawith 17p deletion. Haematologica 2014;99:1350-5.
24. Pettitt AR, Jackson R, Carruthers S, Dodd J, Dodd S, Oates M, et al. Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trial. J Clin Oncol 2012;30:1647-55.
25. Castro JE, Sandoval-Sus JD, Bole J, Rassenti L, Kipps TJ. Rituximab in combination with high-dose methylprednisolone for the treatment of fludarabine refractory high-risk chronic lymphocytic leukemia. Leukemia 2008;22:2048-53.
26. Tsimberidou AM, Wierda WG, Wen S, Plunkett W, O'Brien S, Kipps TJ, et al. Phase I-II clinical trial of oxaliplatin, fludarabine, cytarabine, and rituximab therapy in aggressive relapsed/refractory chronic lymphocytic leukemia or Richter syndrome. Clin Lymphoma Myeloma Leuk 2013;13:568-74.
27. Stephens DM, Ruppert AS, Maddocks K, Andritsos L, Baiocchi R, Jones J, et al. Cyclophosphamide, alvocidib (flavopiridol), and rituximab, a novel feasible chemoimmunotherapy regimen for patients with high-risk chronic lymphocytic leukemia. Leuk Res 2013;37:1195-9.
28. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, et al. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical-translational study from the chronic lymphocytic leukemia research consortium. J Clin Oncol 2014;32:2067-73.
29. O'Brien S, Furman R, Coutre S, Flinn I, Burger J, Blum K, et al. Independent evaluation of ibrutinib efficacy 3 years post-initiation of monotherapy in patients with chronic lymphocytic leukemia/small lymphocytic leukemia including deletion 17p disease. J Clin Oncol 32:5s, 2014(suppl; abstr 7014).
30. Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, et al. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del (17p13.1) karyotype at a single center. Leukemia 2014;28:1365-8.
31. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008;111:5446-56.
32. Chemotherapeutic options in chronic lymphocytic leukemia: a metaanalysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999;91:861-8.
33. Morrison VA. Infectious complications in patients with chronic lymphocytic leukemia: pathogenesis, spectrum of infection, and approaches to prophylaxis. Clin Lymphoma Myeloma 2009;9:365-70.
34. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, et al. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. N Engl J Med 2014;370:2286-94.
35. Klein L, Boxer M, Kolibaba KS, Hawkins MJ, Di Paolo JA, Hu J, et al. Phase 2 trial of GS-9973, a selective syk inhibitor, in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). J Clin Oncol 32:5s, 2014(suppl; abstr 7059).
36. Blachly JS, Byrd JC. Emerging drug profile: cyclin-dependent kinase inhibitors. Leuk Lymphoma 2013;54:2133-43.
37. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014;370:1101-10.
38. Woyach JA, Awan F, Flinn IW, Enoch R, Foster PA, Byrd JC. Final results of a phase I study of the Fc engineered CD19 antibody XmAb (R) 5574 (MOR00208) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Blood 2012;120:2894.
39. Awan FT, Lapalombella R, Trotta R, Butchar JP, Yu B, Benson DM Jr, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood 2010;115:1204-13.
40. Byrd JC, Pagel JM, Awan FT, Forero A, Flinn IW, Deauna-Limayo DP, et al. A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 2014;123:1302-8.
41. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 2013;19:202-8.
42. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 2011;365:725-33.
43. Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73.
44. Kalos M, Levine BL, Macatee TL, Kulikovskaya I, Suppa E, Jena B, et al. Sustained functional T cell persistence and B cell aplasia following CD19-targeting adoptive T cell immunotherapy for relapsed, refractory CD19+ malignacy. In: Proceedings of the 54th ASH Annual Meeting and Exposition; 2012 November 16. Atlanta, GA. p. 756.
45. Grupp SA, Porter DL, Teachey DT, Barrett DM, Chew A, Suppa E, et al. CD19-redirected chimeric antigen receptor T (CART19) cells induce a cytokine release syndrome (CRS) and induction of treatable macrophage activation syndrome (MAS) that can be managed by the IL-6 antagonist tocilizumab (toc). Blood 2012;120:2604.